retatrutide phase 3 trial Lilly orforglipron oral GLP-1 weight loss Retatrutide Achieves Up to 30.3%

Maca Root (Lepidium meyenii) A nutrient-dense Peruvian root traditionally used in mens reproductive nutrition, included to complement the formulation

AO-3RT 12MG TRI-AGONIST PEPTIDE FOR RESEARCH | METABOLISM, OBESITY & ENERGY STUDIES

Over the whole study period semaglutide was the most common first-time medication (n = 1,298,442), however in September 2025 tirzepatide is the most commonly prescribed first-time medication

Optimizing metabolic health, nutrient status, and inflammation naturally remains foundational to improving fertility outcomes, whether or not GLP-1s are part of your care plan

The obesity segment is expected to witness substantial growth rate of CAGR 55.21% during the forecast period as the global burden of obesity continues to escalate, driving demand for effective pharmacological interventions